CTKB - Cytek Biosciences, Inc. Stock Price and Quote

CTKB [NASD]

Index	-	P/E	-	EPS (ttm)	-0.01	Insider Own	11.80%	Shs Outstand	134.71M	Perf Week	6.94%
Market Cap	1.54B	Forward P/E	67.69	EPS next Y	0.17	Insider Trans	-1.77%	Shs Float	111.55M	Perf Month	20.60%
Income	-1.00M	PEG	-	EPS next Q	0.05	Inst Own	53.10%	Short Float / Ratio	3.56% / 6.65	Perf Quarter	-23.46%
Sales	154.60M	P/S	9.97	EPS this Y	-100.00%	Inst Trans	6.31%	Short Interest	3.97M	Perf Half Y	-8.52%
Book/sh	3.09	P/B	3.79	EPS next Y	15.33%	ROA	-0.20%	Target Price	16.50	Perf Year	-13.00%
Cash/sh	2.60	P/C	4.51	EPS next 5Y	-	ROE	-0.20%	52W Range	7.38 - 16.05	Perf YTD	14.69%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	1.50%	52W High	-27.04%	Beta	-
Dividend %	-	Quick Ratio	9.50	Sales past 5Y	-	Gross Margin	61.60%	52W Low	58.67%	ATR	0.58
Employees	574	Current Ratio	10.70	Sales Q/Q	17.70%	Oper. Margin	-0.30%	RSI (14)	55.94	Volatility	4.35% 5.48%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	295.10%	Profit Margin	-0.60%	Rel Volume	0.70	Prev Close	11.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 09 AMC	Payout	-	Avg Volume	596.96K	Price	11.71
Recom	2.20	SMA20	6.64%	SMA50	0.04%	SMA200	-3.19%	Volume	418,422	Change	-1.84%

Jan-06-22

Resumed

Piper Sandler

Overweight

$20

Dec-30-22 11:54AM	Cytek Biosciences (NASDAQ:CTKB) shareholders have endured a 37% loss from investing in the stock a year ago Simply Wall St.
Dec-19-22 08:42AM	Should You Invest in Cytek Biosciences (CTKB) for a Long-Term? Insider Monkey
Nov-21-22 04:05PM	Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference GlobeNewswire
Nov-15-22 10:00AM	Cytek® Biosciences Introduces Cytek Cloud GlobeNewswire
Nov-11-22 05:45AM	Cytek Biosciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St.
05:45PM	Loading…
Nov-09-22 05:45PM	Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates Zacks -5.65%
04:05PM	Cytek Biosciences Reports Third Quarter 2022 Financial Results GlobeNewswire
Oct-31-22 04:30PM	Cytek® Biosciences Names Chris Williams Chief Operating Officer GlobeNewswire
Oct-26-22 04:05PM	Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022 GlobeNewswire
08:00AM	Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference GlobeNewswire
Oct-23-22 07:39PM	Can the New Diagnostic Tools Boost Cytek Biosciences (CTKB)s Valuation? Insider Monkey
Oct-14-22 09:35AM	In the wake of Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest US$70m market cap drop, institutional owners may be forced to take severe actions Simply Wall St.
Sep-07-22 01:27AM	RGAIA Investment: Cytek Biosciences (CTKB) is Profitable Today & Will be Even More So in the Future Insider Monkey +5.29%
Aug-30-22 04:05PM	Cytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-27-22 02:02AM	RGA Investment Advisors Expects Surprising Returns From Cytek Biosciences (CTKB) Insider Monkey
05:25PM	Loading…
Aug-10-22 05:25PM	Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates Zacks +5.17%
05:00PM	Edited Transcript of CTKB.OQ earnings conference call or presentation 10-Aug-22 9:00pm GMT Thomson Reuters StreetEvents
04:05PM	Cytek Biosciences Reports Second Quarter 2022 Financial Results GlobeNewswire
Jul-23-22 09:17AM	The past year for Cytek Biosciences (NASDAQ:CTKB) investors has not been profitable Simply Wall St.
Jul-21-22 08:00AM	Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference GlobeNewswire
Jul-20-22 04:05PM	Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022 GlobeNewswire
Jun-01-22 04:05PM	Cytek Biosciences to Host Inaugural Analyst and Investor Day GlobeNewswire
May-24-22 10:00AM	Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit GlobeNewswire
May-11-22 04:05PM	Cytek Biosciences Reports First Quarter 2022 Financial Results GlobeNewswire -7.84%
May-07-22 09:23AM	What Is The Ownership Structure Like For Cytek Biosciences, Inc. (NASDAQ:CTKB)? Simply Wall St.
Apr-28-22 04:05PM	Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022 GlobeNewswire +5.35%
08:00AM	Cytek Biosciences Appoints Todd Garland Chief Commercial Officer GlobeNewswire
Feb-23-22 04:05PM	Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-16-22 04:05PM	Cytek to Participate in the 42nd Annual Cowen Health Care Conference GlobeNewswire
Feb-11-22 08:00AM	Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 GlobeNewswire
05:38PM	Loading…
Jan-25-22 05:38PM	Reilly Financial Advisors, Llc Buys Sony Group Corp, The Toronto-Dominion Bank, Carrier Global ... GuruFocus.com -5.53%
Jan-21-22 05:54AM	Should Cytek Biosciences, Inc. (NASDAQ:CTKB) Focus On Improving This Fundamental Metric? Simply Wall St.
Jan-05-22 10:00AM	Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity GlobeNewswire
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Nov-25-21 10:00AM	Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks
07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital Insider Monkey
Nov-17-21 10:00AM	Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System GlobeNewswire
Nov-08-21 04:05PM	Cytek Biosciences Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-03-21 08:00AM	Cytek Biosciences Acquires Tonbo Biosciences Cell Analysis Business GlobeNewswire
Oct-26-21 04:05PM	Cytek Biosciences to Report Third Quarter Financial Results on November 8, 2021 GlobeNewswire
Oct-23-21 08:46AM	What Is The Ownership Structure Like For Cytek Biosciences, Inc. (NASDAQ:CTKB)? Simply Wall St.
Oct-07-21 10:00AM	Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay GlobeNewswire
Sep-02-21 04:05PM	Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference GlobeNewswire +16.98%
04:03PM	Cytek Biosciences Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-02-21 04:01PM	Cytek Biosciences Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +7.80%
Jul-27-21 06:00PM	Cytek Biosciences Announces Closing of Its Initial Public Offering GlobeNewswire

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jeanmonod Patrik	Chief Financial Officer	Jan 24	Sale	11.05	3,500	38,675	76,132	Jan 25 07:20 PM
Yan Ming	Chief Technology Officer	Jan 19	Sale	11.03	20,000	220,600	7,946,833	Jan 20 06:26 PM
Jiang Wenbin	President and CEO	Jan 09	Sale	10.66	20,000	213,200	7,740,314	Jan 10 06:26 PM
Jeanmonod Patrik	Chief Financial Officer	Dec 27	Sale	9.77	3,500	34,195	79,632	Dec 29 01:03 PM
Yan Ming	Chief Technology Officer	Dec 19	Sale	10.38	20,000	207,600	7,966,833	Dec 20 07:07 PM
Jiang Wenbin	President and CEO	Dec 07	Sale	11.86	20,000	237,200	7,760,314	Dec 09 05:57 PM
Ball Jack	Director	Nov 29	Option Exercise	0.69	23,999	16,533	26,999	Nov 30 07:39 PM
Jeanmonod Patrik	Chief Financial Officer	Nov 25	Sale	14.30	3,500	50,050	83,132	Nov 28 06:55 PM
Yan Ming	Chief Technology Officer	Nov 21	Sale	14.66	20,000	293,200	7,986,833	Nov 22 06:15 PM
Ball Jack	Director	Nov 14	Option Exercise	0.40	16,000	6,400	19,000	Nov 16 05:53 PM
Ball Jack	Director	Nov 14	Sale	14.69	16,000	235,040	3,000	Nov 16 05:53 PM
Jiang Wenbin	President and CEO	Nov 07	Sale	14.76	20,000	295,200	7,785,820	Nov 08 05:44 PM
Jeanmonod Patrik	Chief Financial Officer	Oct 24	Sale	15.16	3,500	53,060	85,563	Oct 25 05:38 PM
Yan Ming	Chief Technology Officer	Oct 19	Sale	14.42	20,000	288,400	8,005,624	Oct 20 06:18 PM
Jiang Wenbin	President and CEO	Oct 07	Sale	14.79	20,000	295,800	7,805,820	Oct 11 05:42 PM
Jeanmonod Patrik	Chief Financial Officer	Sep 26	Sale	12.63	3,500	44,205	89,063	Sep 28 05:38 PM
Yan Ming	Chief Technology Officer	Sep 19	Sale	12.42	20,000	248,400	8,025,624	Sep 20 05:47 PM
Jiang Wenbin	President and CEO	Sep 07	Sale	12.89	20,000	257,800	7,825,820	Sep 09 08:06 PM
Jeanmonod Patrik	Chief Financial Officer	Aug 24	Sale	13.45	3,500	47,075	92,563	Aug 25 06:14 PM
Yan Ming	Chief Technology Officer	Aug 19	Sale	13.62	20,000	272,400	8,045,624	Aug 19 07:41 PM
Jiang Wenbin	President and CEO	Aug 08	Sale	15.09	20,000	301,800	7,841,541	Aug 10 05:59 PM
Jeanmonod Patrik	Chief Financial Officer	Aug 01	Sale	12.80	3,500	44,800	94,994	Aug 03 05:49 PM
Yan Ming	Chief Technology Officer	Jul 19	Sale	11.83	20,000	236,600	8,064,415	Jul 20 06:14 PM
Jiang Wenbin	President and CEO	Jul 07	Sale	11.19	20,000	223,800	7,861,541	Jul 08 05:59 PM
Yan Ming	Chief Technology Officer	Jun 21	Sale	10.06	20,000	201,200	8,084,415	Jun 22 07:07 PM
Jiang Wenbin	President and CEO	Jun 07	Sale	10.75	20,000	215,000	7,881,541	Jun 09 08:08 PM
Yan Ming	Chief Technology Officer	May 19	Sale	9.92	20,000	198,400	8,104,415	May 20 07:19 PM
Jiang Wenbin	President and CEO	May 09	Sale	8.01	20,000	160,200	7,896,040	May 12 09:18 AM
Yan Ming	Chief Technology Officer	Apr 19	Sale	10.34	20,000	206,800	8,122,803	Apr 21 08:58 PM
Jiang Wenbin	President and CEO	Apr 07	Sale	10.54	20,000	210,800	7,916,040	Apr 08 05:33 PM
Yan Ming	Chief Technology Officer	Mar 21	Sale	11.64	20,000	232,800	8,142,803	Mar 23 06:03 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 15	Buy	12.27	241,727	2,964,999	13,381,054	Mar 16 05:10 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 14	Buy	12.35	342,143	4,223,926	13,139,327	Mar 16 05:10 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 11	Buy	12.77	337,492	4,309,334	12,797,184	Mar 11 05:27 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 10	Buy	12.95	256,992	3,327,584	12,459,692	Mar 11 05:27 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 09	Buy	12.99	40,154	521,753	12,202,700	Mar 11 05:27 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 08	Buy	12.86	245,701	3,160,059	12,162,546	Mar 08 04:59 PM
Yan Ming	Chief Technology Officer	Mar 07	Option Exercise	0.35	73,011	25,325	8,162,803	Mar 08 05:57 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 07	Buy	12.61	337,901	4,260,965	11,916,845	Mar 08 04:59 PM
Jiang Wenbin	President and CEO	Mar 07	Sale	12.65	20,000	253,052	7,936,040	Mar 08 05:55 PM
Jiang Wenbin	President and CEO	Mar 04	Option Exercise	0.25	66,665	16,666	7,956,040	Mar 08 05:55 PM
Barnett Valerie	General Counsel	Mar 04	Option Exercise	4.71	10,500	49,455	12,400	Mar 08 05:51 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04	Buy	12.99	63,662	827,230	11,578,944	Mar 08 04:59 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 02	Buy	12.89	138,255	1,782,218	11,515,282	Mar 02 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 01	Buy	12.98	294,864	3,826,303	11,377,027	Mar 02 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 28	Buy	12.97	8,746	113,430	11,082,163	Mar 02 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 25	Buy	12.99	18,991	246,699	11,073,417	Feb 25 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 24	Buy	13.03	186,467	2,429,851	11,054,426	Feb 25 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 23	Buy	13.41	214,922	2,883,114	10,867,959	Feb 25 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 22	Buy	13.46	214,922	2,892,055	10,653,037	Feb 22 05:22 PM
Yan Ming	Chief Technology Officer	Feb 22	Sale	13.44	20,000	268,800	8,089,792	Feb 24 05:41 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 18	Buy	14.12	166,229	2,346,389	10,438,115	Feb 22 05:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 17	Buy	14.78	166,229	2,457,264	10,271,886	Feb 22 05:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 16	Buy	14.98	166,200	2,489,377	10,105,657	Feb 16 07:39 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 15	Buy	14.99	166,200	2,490,524	9,939,457	Feb 16 07:39 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 14	Buy	14.72	166,229	2,446,924	9,773,257	Feb 16 07:39 PM
Yan Ming	Chief Technology Officer	Feb 10	Sale	15.11	20,000	302,106	8,109,792	Feb 14 06:23 PM
Jiang Wenbin	President and CEO	Feb 07	Sale	14.40	20,000	288,000	7,889,375	Feb 09 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience